Sarcura

Sarcura is a biotechnology startup based in Austria, founded in 2019. The company's slogan, "Powering New Possibles in Cell Therapy Manufacturing," encapsulates its mission to address the challenges of manufacturing patient-derived cell therapies. By leveraging cutting-edge semiconductor technologies, including silicon photonics integrated into microfluidic cartridges, Sarcura aims to revolutionize the industry. The company's focus on creating fully automated manufacturing systems with real-time process and product control has the potential to significantly enhance the scalability and quality of cell therapies. In its latest funding round, €7.05M was secured from a consortium of investors including HCVC, Tecnet Equity, Nina Ventures, NovaCapital, Axilium Holding, xista science ventures, and Lansdowne Investment Company Cyprus on 17 November 2022. The funds are intended to further develop Sarcura's pioneering platform, with the ambitious goals of achieving a 100x production boost and a 10x cost reduction in cell therapy manufacturing. This investment signifies a strong endorsement of Sarcura's vision to democratize access to cost-effective and secure cell therapies, ultimately reshaping the future of cancer treatment. For more information, visit www.sarcura.com.